XGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Exagen Inc (XGN) does not present a compelling buy opportunity for a beginner, long-term investor at this time. While the company has shown revenue growth, the financial performance, reduced analyst price targets, and lack of strong positive catalysts suggest waiting for a clearer growth trajectory or improved sentiment.
The technical indicators are neutral. MACD is slightly positive but contracting, RSI is in the neutral zone at 54.796, and moving averages are converging. The stock is trading near its pivot point of 3.081, with resistance at 3.224 and support at 2.937.
Revenue increased 21.79% YoY in Q4 2025, and volume growth has been strong. Analysts expect potential ASP upside in FY26 and FY27, along with a return to double-digit revenue growth in 2027.
Gross margin dropped 10.84% YoY, and net income remains negative. Analysts have significantly lowered price targets due to muted ASP and gross margin expansion. No recent news or significant trading trends from hedge funds, insiders, or Congress.
In Q4 2025, revenue increased to $16.63M (up 21.79% YoY), net income improved to -$4.67M (up 24.25% YoY), and EPS remained flat at -0.2. However, gross margin dropped to 55.35% (down 10.84% YoY).
Analysts maintain Buy ratings but have significantly lowered price targets (from $12-$18 to $8-$10). They cite ASP and gross margin challenges as key concerns, though they anticipate improvement in the long term.
